Differential [qlco]
effects [qlco]
Raloxifene [orch, phsu]
Estrogen [horm, phsu, strd]
Insulin Sensitivity [patf]
postmenopausal [tmco]
Women [popg]
objectives [inpr]
Test [lbpr]
Hypothesis [idcn]
Raloxifene [orch, phsu]
Estrogen [horm, phsu, strd]
Insulin Sensitivity [patf]
postmenopausal [tmco]
Women [popg]
magnitude [qnco]
Drugs [phsu]
Design [acty]
placebo controlled study [inpr, resa]
DOUBLE BLIND [resa]
randomized [resa]
setting [ftcn]
General [spco]
Clinical Center [orgt]
University Medical Center [hcro, mnob]
Michigan [geoa]
university hospital [hcro, mnob]
participants [popg]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Old [tmco]
Mean deviation [clna]
Age [orga]
Standard [qlco]
Receive [qlco]
Hormone replacement therapy [topp]
intervention [hlca]
Eight [qnco]
weeks [tmco]
Drug Therapy [topp]
Randomization [resa]
Raloxifene [orch, phsu]
N NOS [aapp, imft]
Estrogen [horm, phsu, strd]
N NOS [aapp, imft]
placebo [topp]
N NOS [aapp, imft]
measurements [ftcn]
Subject [grup]
Frequently [tmco]
sampled [diap]
Intravenous Glucose Tolerance Test [diap]
Insulin Sensitivity [patf]
regional [spco]
Central [spco]
Body measurements [fndg]
Composition [clna]
Dual-Energy X-Ray Absorptiometry [diap]
baseline [bodm]
weeks [tmco]
Drug Therapy [topp]
statistically significant [qnco]
Age [orga]
Body Mass Index [diap]
Central [spco]
Mass [fndg]
Sensitivity [qnco]
Group [idcn]
baseline [bodm]
Variable [qlco]
Sensitivity [qnco]
weeks [tmco]
Drug Therapy [topp]
Sensitivity [qnco]
placebo [topp]
Group [idcn]
Estrogen [horm, phsu, strd]
Group [idcn]
Decrease [qlco]
Sensitivity [qnco]
Raloxifene [orch, phsu]
Group [idcn]
P NOS [aapp, imft]
Estrogen [horm, phsu, strd]
Ability [orga]
Maintain [acty]
Insulin Sensitivity [patf]
Raloxifene [orch, phsu]
Decrease [qlco]
Insulin Sensitivity [patf]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Clinical Significance [fndg]
Raloxifene [orch, phsu]
Insulin Sensitivity [patf]
postmenopausal [tmco]
Women [popg]
Evaluation [ftcn]
Future [tmco]
